Redmile Group, LLC - PROQR THRAPEUTICS N V ownership

PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 37 filers reported holding PROQR THRAPEUTICS N V in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.5%.

Quarter-by-quarter ownership
Redmile Group, LLC ownership history of PROQR THRAPEUTICS N V
ValueSharesWeighting
Q3 2018$28,075,000
+458.6%
1,450,925
-6.9%
0.86%
+294.5%
Q4 2017$5,026,000
-35.3%
1,558,392
-2.8%
0.22%
-42.8%
Q3 2017$7,774,000
-6.3%
1,602,975
+0.4%
0.38%
-24.2%
Q2 2017$8,301,000
+6.9%
1,596,275
+2.8%
0.50%
+0.2%
Q1 2017$7,766,000
+0.4%
1,553,225
-1.6%
0.50%
-24.4%
Q4 2016$7,733,000
+101.3%
1,578,174
+174.1%
0.67%
+118.7%
Q3 2016$3,841,000
+36.4%
575,863
-1.0%
0.30%
+13.4%
Q2 2016$2,815,000
+4.4%
581,638
+5.2%
0.27%
-2.5%
Q1 2016$2,697,000
-44.2%
552,713
-0.8%
0.28%
-23.8%
Q4 2015$4,836,000
-49.8%
557,193
-15.7%
0.36%
-50.3%
Q3 2015$9,628,000
+11.8%
660,816
+27.9%
0.73%
+3.3%
Q2 2015$8,613,000
-47.6%
516,690
-31.2%
0.71%
-52.2%
Q1 2015$16,436,000
+4.5%
751,1710.0%1.48%
-13.8%
Q4 2014$15,729,000
+30.3%
751,171
-1.8%
1.71%
+22.9%
Q3 2014$12,067,000765,2321.39%
Other shareholders
PROQR THRAPEUTICS N V shareholders Q3 2018
NameSharesValueWeighting ↓
Aquilo Capital Management, LLC 748,861$6,815,0002.37%
Opus Point Partners Management, LLC 138,461$1,260,0001.86%
RTW INVESTMENTS, LP 3,722,950$33,879,0001.81%
Kerrisdale Advisers, LLC 465,580$4,237,0001.52%
DAFNA Capital Management LLC 261,521$2,380,0000.90%
SPHERA FUNDS MANAGEMENT LTD. 470,000$4,277,0000.58%
Artal Group S.A. 1,300,000$11,830,0000.48%
Orbimed Advisors 1,382,502$12,581,0000.20%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 56,000$511,0000.19%
ALTRINSIC GLOBAL ADVISORS LLC 201,360$1,832,0000.08%
View complete list of PROQR THRAPEUTICS N V shareholders